University Deal Valuations
Executive Summary
How do the financial terms of deals signed with university tech transfer offices differ when the licensor is a biotech, compared to a Big Pharma? We broke out university deals signed by these kinds of licensors to find out.
You may also be interested in...
Royalties in Tech Transfer Alliances
In Vivo reviews recent royalty rates in tech transfer-to-biotech licensing deals.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.